Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
DNAthis companyGinkgo Bioworks Holdings, Inc.	$12.19	-1.47×	0.91×	2.71×	-2.88×	-427.1%	81.5%	-185.3%	-183.8%	-61.5%	-30.0%	-38.8%	0.86×	-1.07×	0×	4.92×	0.0%	2	-8.71	1	C-
ARVNArvinas, Inc.	$6.52	-9.27×	1.77×	2.93×	-8.44×	-1590.9%	98.0%	-43.8%	-30.8%	-18.6%	-19.9%	-35.8%	0.02×	1.78×	0×	4.92×	0.0%	3	0.86	3	B-
AVBPArriVent BioPharma, Inc.	$13.98	-4.66×	2.52×	0×	-4.38×	-92.2%	0.0%	0.0%	0.0%	-54.1%	-57.8%	-20.8%	0×	0.27×	0×	12.83×	0.0%	2	12.15	2	C+
IOVAIovance Biotherapeutics, Inc.	$8.54	-2.5×	1.4×	3.7×	-2.45×	-50.5%	34.3%	-151.1%	-148.4%	-56.0%	-50.9%	-34.5%	0.07×	0.33×	0×	3.2×	0.0%	4	7.46	2	C
MBXMBX Biosciences, Inc. Common Stock	$54.54	-13.25×	3.12×	0×	-12.42×	-96.3%	0.0%	0.0%	0.0%	-23.6%	-26.5%	-7.1%	0×	0.86×	0×	24.62×	0.0%	1	58.99	2	C
MGTXMeiraGTx Holdings plc	$9.40	-5.6×	-110.38×	7.86×	-7.4×	-554.4%	94.0%	-130.2%	-140.3%	1971.4%	-70.9%	-7.8%	-15.31×	-0.25×	-8.69×	0.75×	0.0%	6	4.07	3	B
Peer median	—	-5.6×	1.77×	2.93×	-7.4×	-96.3%	34.3%	-43.8%	-30.8%	-23.6%	-50.9%	-20.8%	0×	0.33×	0×	4.92×	0.0%	3	7.46	2	—